SHANDONG, China, Jan. 25 /PRNewswire-Asia-FirstCall/ -- China YCT International Group, Inc. ("China YCT" or the "Company") (OTC Bulletin Board: CYIG) today announced that on December 23, 2009 the State Intellectual Property Office of the People's Republic of China approved the patent application of its operating subsidiary, Shandong Spring Pharmaceutical Co., Ltd., for "a unique method of making ginkgo tea, and the manufacturing technology." This patent represents a key addition to the Company's growing intellectual property portfolio.
China YCT's technology improves the methods traditionally employed in the gingko tea health care products industry, and provides a faster, more efficient method of offering the public gingko tea. Studies have shown that Gingko tea has memory-enhancing benefits for people. "Our method of producing gingko tea increases the memory-enhancing ingredients as compared to the traditional gingko products, so our products will provide increased resistance to memory loss, whether short- or long-term," said Mr. Tinghe Yan, Chairman and CEO of China YCT.
The Company's new products can slow down the platelet activating factor (PAF) to stop it from over stimulation. Medical studies have shown that excess production of PAF can result in various inflammation-related diseases, including damage to the brain. In addition, like all other properly made gingko tea products, the Company's new products help reduce cholesterol and aid in blood circulation, thus reducing the risk of heart disease.
In order to maximize the benefits of gingko, the Company's R&D team
developed a new and unique production method. "Our unique new gingko tea
products, which will provide many physical benefits to people that other
gingko teas canno
|SOURCE China YCT International Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved